Lilly's Once-Weekly Insulin Efsitora Meets Main Goals Across Three Phase 3 Trials In Type 2 Diabetes

June 22, 2025 06:31 PM PDT | By EODHD

Google News:

Lilly's Once-Weekly Insulin Efsitora Meets Main Goals Across Three Phase 3 Trials In Type 2 Diabetes — Image source: Kalkine Media

Recent News

DNTH (NASDAQ:DNTH) Earnings Biotech Development Path Russell 1000

NICE (NASDAQ:NICE) Earnings Forecast Update Reflects Technology Sector...

RLI (NYSE:RLI) Earnings Forecast Raised in Insurance Sector Growth Upd...

NetApp (NASDAQ:NTAP) Earnings Raised Nasdaq Composite

(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand. In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.

In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand. In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand. In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. Across the three trials, efsitora demonstrated an overall safety profile comparable to two of the most commonly used daily basal insulin therapies for type 2 diabetes. In QWINT-1, efsitora was associated with approximately 40% fewer hypoglycemic events than insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure at 0.50 for efsitora versus 0.88 for insulin glargine at 52 weeks.

In QWINT-3, the respective rates were 0.84 for efsitora and 0.74 for insulin degludec at 78 weeks. In QWINT-4, the rates were 6.6 for efsitora and 5.9 for insulin glargine at 26 weeks. Lilly said it plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.